AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01688791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Study NCT01739517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven Therapy
Description: After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
Study NCT03099785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifamycin SV 600mg t.i.d.
Description: Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
Study NCT03099785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifamycin SV b.i.d. + Placebo
Description: Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
Study NCT03099785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo t.i.d.
Description: Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
Study NCT03805360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
Study NCT01688791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03014661 — intervention group
Intervention type: OTHER
Intervention: Quality of life under or after therapy with Pollinex quattro
Description: To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
Study NCT00204893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium formate
Description: Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
Study NCT02937103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD123-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study NCT01688791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT03805360 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
Study NCT01582282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: fiber-free placebo
Study NCT04376476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood samples will be taken as below: Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
Study NCT01582282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3.4 g psyllium BID
Description: 3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
Study NCT01582282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 6.8g psyllium BID
Description: 6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
Study NCT04376476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low or upper respiratory tract sample
Description: Low or upper respiratory tract sample will be collected in order to take virology measurements:~Group E1: At day 0 Group E2: At day 0, day 7, day 14 Group E3: At day 0
Study NCT04376476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stool collection or fecal swab
Description: The stool collection or fecal swab will be collected in order to take virology measurements:~Group E1: / Group E2: At day 0, day 7, day 14 Group E3: At day 0
Study NCT04376476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone call
Description: phone calls will be performed to collect data regarding patients' symptoms at: Group E1: Day 14 Group E3: Day 14
Study NCT02106767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg po x1
Study NCT02106767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin plus rifampin
Description: Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
Study NCT03796689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-linked HBPM and associated app
Description: Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publicly available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
Study NCT03796689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard HBPM
Description: Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publicly available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
Study NCT04252937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: HAM8101 (Adrecizumab) is a humanized IgG1 monoclonal antibody (mAb).
Study NCT00414414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT00414414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03504605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online self-compassion intervention
Description: Parents are asked to write in an online text box about a parenting event in which they felt shame. They are then given a validated set of instructions asking them to reflect on the event and write self-compassionate responses.
Study NCT01055886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Nicotine patch, 7-21 mg.
Study NCT01055886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: placebo patch used from weeks 4-6
Study NCT03261817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity (APA)
Description: 2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition
Study NCT03261817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity (APA)
Description: 2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition
Study NCT03261817 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Education program (HE)
Description: 2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
Study NCT03483350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Ampoule
Study NCT03483350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Ampoule
Study NCT04284007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural levobupivacaine
Description: Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
Study NCT04284007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone in addition to levobupivacaine
Description: Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
Study NCT03406429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
Study NCT03406429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM rTMS
Description: All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
Study NCT02991287 — intervention group
Intervention type: PROCEDURE
Intervention: Inguinal hernia repair
Study NCT00814073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib 6 mg/kg/day
Study NCT00814073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00814073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
Study NCT00814073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
Study NCT02991287 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal hysterectomy
Study NCT02031380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open angle glaucoma - iDropper device
Description: The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
Study NCT02991287 — intervention group
Intervention type: PROCEDURE
Intervention: Vaginal hysterectomy
Study NCT00400933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psycho-education
Description: six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
Study NCT03736837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Icotinib
Description: Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study NCT00371033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: dosage
Study NCT00371033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dosage
Study NCT02490150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Study NCT02490150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corifollitropin alfa
Study NCT02991287 — intervention group
Intervention type: PROCEDURE
Intervention: Thoracotomy
Study NCT03623711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
Study NCT04359823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 2%, 2% Cholesterol Cream
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
Study NCT04359823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 2% Cream
Description: Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
Study NCT00540176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Description: Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
Study NCT03714386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A synthetic high-flux dialyzer will be used for OL-HDF.
Description: A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
Study NCT03714386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A medium cut-off dialyzer will be used for HDx.
Description: A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
Study NCT01958034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberry extract
Study NCT02991053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Study NCT03623711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
Study NCT03623711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
Study NCT03623711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Healthy control
Description: Healthy control take placebo tablets
Study NCT01977976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial aspiration by pipelle
Description: Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
Study NCT00855166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet oral 10 mg total daily dose once daily 102 weeks
Study NCT00855166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
Study NCT00855166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
Study NCT00855166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Tablet oral 100 mg total daily dose once daily rescue medication
Study NCT00855166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Tablet oral 100 mg total daily dose once daily rescue medication
Study NCT00855166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
Study NCT02478749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arm retraction
Description: gently pulling through the ipsilateral arm to the knee
Study NCT03725527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Block
Description: Sonar guided RSB will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
Study NCT01272258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: SC injection
Study NCT01272258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study NCT00489476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Loxapine
Study NCT00489476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Staccato Placebo
Description: Placebo aerosol inhalation (0mg)
Study NCT02011542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: This is a probiotic mixture
Study NCT02011542 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a pill with inactive ingredients.
Study NCT03248661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Now I'm Telling You
Description: Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
Study NCT03503994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled Beclomethasone Dipropionate Monohydrate
Description: Beclomethasone Dipropionate (HFA-BDP, QVAR\*) in the following doses will be evaluated:~1. 200 mcg bid~2. 400 mcg bid~3. 600 mcg bid~4. 800 mcg bid
Study NCT03232177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagre Cap.
Description: from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
Study NCT03958617 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bilateral Deep brain stimulation of the thalamus, Medtronic Device
Study NCT03958617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Deep brain stimulation of the thalamus, Medtronic Device
Study NCT04297384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive standard chemotherapy educational materials
Study NCT04297384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive personalized information about cancer, treatment, and side effects
Study NCT04297384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04297384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04297384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete surveys
Study NCT02098473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC4046
Study NCT02098473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05600257 — intervention group
Intervention type: DEVICE
Intervention: DBT
Description: Image with digital breast tomosynthesis
Study NCT05600257 — intervention group
Intervention type: DEVICE
Intervention: DM
Description: Image with digital mammography
Study NCT00619398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Oral
Study NCT00619398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506MR capsule
Description: Oral
Study NCT02118246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling was performed for one week, three times a week.
Study NCT02118246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio tape was performed for one week, three times a week.
Study NCT01485367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene gel 0.3%
Description: A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
Study NCT04203771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic AB-DENTALAC
Description: Orodispersible tablets containing Lactobacillus plantarum \[now Lactoplantibacillus plantarum\] KABP051 (CECT7481) and Lactobacillus brevis \[now Levilactobacillus brevis\] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10\^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
Study NCT04203771 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
Study NCT04203771 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical removal of mandibular third molars at baseline
Description: Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.